Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.704
C. Y. Quan, Xiaoli Wang, Qijun Zhang
Quan et al. : Impact of Early Goal-Directed Therapy in the Prognosis of Septic Shock To assess the efficacy of early goal-directed therapy in conjunction with glucocorticoids on the prognosis of septic shock is the objective of the study. 60 septic shock patients admitted to the hospital from June 2019 to August 2022 were split into control cohort and observation cohort according to the method of random number table, with 40 patients in every cohort. Both cohorts underwent standard therapy, with the observation cohort additionally receiving intravenous hydrocortisone drip and early goal-directed therapy, all of which were continuously treated for 7 d. The baseline data of all patients, such as sex, age, infection site, sequential organ failure assessment score and immune cell level, were recorded in detail, and the C-reactive protein, intensive care unit hospitalization time, and the duration of mechanical ventilation was observed for patients. The therapeutic impact of early goal-directed therapy combined with glucocorticoids on septic shock in the analysis period aims to inform the optimal therapy strategy selection. Following therapy, the cluster of differentiation 4 + , cluster of differentiation 8 + and cluster of differentiation 4 + /cluster of differentiation 8 + ratios in both the therapy and control cohorts increased significantly, exhibiting statistical significance. The therapy cohort demonstrated a notable decrease in C-reactive protein, intensive care unit hospitalization duration and mechanical ventilation time when compared to the control cohort, with the difference being statistically significant. Early goal-directed therapy combined with glucocorticoid can enhance the cellular immune function of patients with septic shock, reduce the systemic inflammatory reaction and improve the prognosis.
{"title":"The Impact of Early Goal-Directed Therapy in Conjunction with Glucocorticoids in the Prognosis of Septic Shock","authors":"C. Y. Quan, Xiaoli Wang, Qijun Zhang","doi":"10.36468/pharmaceutical-sciences.spl.704","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.704","url":null,"abstract":"Quan et al. : Impact of Early Goal-Directed Therapy in the Prognosis of Septic Shock To assess the efficacy of early goal-directed therapy in conjunction with glucocorticoids on the prognosis of septic shock is the objective of the study. 60 septic shock patients admitted to the hospital from June 2019 to August 2022 were split into control cohort and observation cohort according to the method of random number table, with 40 patients in every cohort. Both cohorts underwent standard therapy, with the observation cohort additionally receiving intravenous hydrocortisone drip and early goal-directed therapy, all of which were continuously treated for 7 d. The baseline data of all patients, such as sex, age, infection site, sequential organ failure assessment score and immune cell level, were recorded in detail, and the C-reactive protein, intensive care unit hospitalization time, and the duration of mechanical ventilation was observed for patients. The therapeutic impact of early goal-directed therapy combined with glucocorticoids on septic shock in the analysis period aims to inform the optimal therapy strategy selection. Following therapy, the cluster of differentiation 4 + , cluster of differentiation 8 + and cluster of differentiation 4 + /cluster of differentiation 8 + ratios in both the therapy and control cohorts increased significantly, exhibiting statistical significance. The therapy cohort demonstrated a notable decrease in C-reactive protein, intensive care unit hospitalization duration and mechanical ventilation time when compared to the control cohort, with the difference being statistically significant. Early goal-directed therapy combined with glucocorticoid can enhance the cellular immune function of patients with septic shock, reduce the systemic inflammatory reaction and improve the prognosis.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigation on Potential Targets of Fuyuan Xingnao Decoction in the Treatment of Intracerebral Hemorrhage Based on Network Pharmacology","authors":"Yanqi Luo, Shuangyang Li, Yanjiao Li, Xue Bai, Bangjiang Fang","doi":"10.36468/pharmaceutical-sciences.spl.702","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.702","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.716
Kaifeng Tang, J. Ye, S. Mao, H. Wang, Yuanyuan Chen
{"title":"Meta-Analysis on Clinical Outcomes of Paclitaxel-Coated Balloon Angioplasty in Femoral Popliteal Artery Occlusion","authors":"Kaifeng Tang, J. Ye, S. Mao, H. Wang, Yuanyuan Chen","doi":"10.36468/pharmaceutical-sciences.spl.716","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.716","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.706
Q. R. Jiang, Siwei Yang, C. C. Lai, Z. M. A. Alsalman, P. Wang, X. L. Hu, W. B. Zhang, Y. X. Wang
{"title":"Activities of Daily Living Predict Contrast-Associated Acute Kidney Injury among Population Undergoing Coronary Angiography","authors":"Q. R. Jiang, Siwei Yang, C. C. Lai, Z. M. A. Alsalman, P. Wang, X. L. Hu, W. B. Zhang, Y. X. Wang","doi":"10.36468/pharmaceutical-sciences.spl.706","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.706","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.699
Lan Li, Jialin Li, Min Wang
{"title":"Clinical Efficacy of Medroxyprogesterone Combined with Different Antibiotics in the Treatment of Chronic Endometritis","authors":"Lan Li, Jialin Li, Min Wang","doi":"10.36468/pharmaceutical-sciences.spl.699","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.699","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1167
B. Manisha, B. Aishwarya, B. Shekar, P. Mahesh, R. Adepu, A. R Sai Pawan
An open label prospective interventional study was conducted on asthma and chronic obstructive pulmonary disease patients to assess the influence of pharmacist provided education on inhaler usage technique and its impact on therapeutic outcomes in patients with Asthma and chronic obstructive pulmonary disease. The study was approved by the institutional ethics committee and conducted in the pulmonology department of Kamineni Institute of Medical Sciences, Narketpalli, Telangana. Written informed consent was obtained from the recruited study patients. A suitably designed data collection form was designed to capture disease and lab details i.e. forced expiratory volume in the 1st second. A newly constructed and validated knowledge, attitude and practices questionnaire was administered to assess the knowledge about the disease and its management. An inhaler checklist was applied to every patient to assess the inhaler usage technique and provided suitable guidance to use the inhaler effectively and assessed the impact of education on the patient's therapeutic outcomes. Among the 20 patients, 11 (55 %) were females and 9 (45 %) were males. The mean age of the study patients was 54±3 y. A significant improvement in knowledge, attitude and practices scores was observed in the post-counselling stage (p<0.001) and inhaler usage technique (p<0.001) among the patient after providing the counselling. Correct education about disease and inhaler usage techniques had shown an improvement in patient ̓s therapeutic outcomes.
{"title":"Influence of Pharmacist Counselling on Inhaler Usage Technique on Therapeutic Outcomes in Asthma and Chronic Obstructive Pulmonary Disease Patients","authors":"B. Manisha, B. Aishwarya, B. Shekar, P. Mahesh, R. Adepu, A. R Sai Pawan","doi":"10.36468/pharmaceutical-sciences.1167","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1167","url":null,"abstract":"An open label prospective interventional study was conducted on asthma and chronic obstructive pulmonary disease patients to assess the influence of pharmacist provided education on inhaler usage technique and its impact on therapeutic outcomes in patients with Asthma and chronic obstructive pulmonary disease. The study was approved by the institutional ethics committee and conducted in the pulmonology department of Kamineni Institute of Medical Sciences, Narketpalli, Telangana. Written informed consent was obtained from the recruited study patients. A suitably designed data collection form was designed to capture disease and lab details i.e. forced expiratory volume in the 1st second. A newly constructed and validated knowledge, attitude and practices questionnaire was administered to assess the knowledge about the disease and its management. An inhaler checklist was applied to every patient to assess the inhaler usage technique and provided suitable guidance to use the inhaler effectively and assessed the impact of education on the patient's therapeutic outcomes. Among the 20 patients, 11 (55 %) were females and 9 (45 %) were males. The mean age of the study patients was 54±3 y. A significant improvement in knowledge, attitude and practices scores was observed in the post-counselling stage (p<0.001) and inhaler usage technique (p<0.001) among the patient after providing the counselling. Correct education about disease and inhaler usage techniques had shown an improvement in patient ̓s therapeutic outcomes.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1174
He Huang, Lei Zhao, Lijun Huang, Xue Wang, Liping Sun
To investigate the influence of harpagide isolated from Scrophularia ningpoensis Hemsl. on human umbilical vascular endothelial cells damage induced by oxidized low-density lipoprotein and its possible mechanism. Human umbilical vascular endothelial cells were cultured in vitro. Different doses (20, 40, 80 μmol/l) of harpagide were applied to treat human umbilical vascular endothelial cells induced by oxidized low-density lipoprotein, human umbilical vascular endothelial cells overexpressing microRNA-140-5p were induced by oxidized low-density lipoprotein, and 80 μg/ml harpagide was applied to treat oxidized low-density lipoprotein induced human umbilical vascular endothelial cells with microRNA-140-5p downregulation. Enzyme-linked immunosorbent assay kits were used to detect malondialdehyde content as well as superoxide dismutase and glutathione peroxidase activities. Flow cytometry and Western blot were utilized to investigate cell apoptosis. Ribonucleic acid expression was analyzed by real-time quantitative reverse transcription polymerase chain reaction. Different doses of harpagide (20, 40, 80 μmol/l) reduced the malondialdehyde content and the rate of apoptosis in oxidized low-density lipoprotein-stimulated human umbilical vascular endothelial cells (p<0.05), while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). MicroRNA-140- 5p overexpression reduced the malondialdehyde content and apoptosis in oxidized low-density lipoproteinstimulated human umbilical vascular endothelial cells while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). Harpagide promoted microRNA-140-5p expression in human umbilical vascular endothelial cells after oxidized low-density lipoprotein stimulation (p<0.05). MicroRNA- 140-5p knockdown reversed the inhibitory effect of harpagide in human umbilical vascular endothelial cells (p<0.05). Harpagide up-regulates microRNA-140-5p to inhibit the oxidative stress and apoptosis of oxidized low-density lipoprotein-induced human umbilical vascular endothelial cells.
{"title":"Harpagide Increases microRNA-140-5p Expression to inhibit Oxidised Low-Density Lipoprotein-Caused Human Umbilical Vascular Endothelial Cell Damage","authors":"He Huang, Lei Zhao, Lijun Huang, Xue Wang, Liping Sun","doi":"10.36468/pharmaceutical-sciences.1174","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1174","url":null,"abstract":"To investigate the influence of harpagide isolated from Scrophularia ningpoensis Hemsl. on human umbilical vascular endothelial cells damage induced by oxidized low-density lipoprotein and its possible mechanism. Human umbilical vascular endothelial cells were cultured in vitro. Different doses (20, 40, 80 μmol/l) of harpagide were applied to treat human umbilical vascular endothelial cells induced by oxidized low-density lipoprotein, human umbilical vascular endothelial cells overexpressing microRNA-140-5p were induced by oxidized low-density lipoprotein, and 80 μg/ml harpagide was applied to treat oxidized low-density lipoprotein induced human umbilical vascular endothelial cells with microRNA-140-5p downregulation. Enzyme-linked immunosorbent assay kits were used to detect malondialdehyde content as well as superoxide dismutase and glutathione peroxidase activities. Flow cytometry and Western blot were utilized to investigate cell apoptosis. Ribonucleic acid expression was analyzed by real-time quantitative reverse transcription polymerase chain reaction. Different doses of harpagide (20, 40, 80 μmol/l) reduced the malondialdehyde content and the rate of apoptosis in oxidized low-density lipoprotein-stimulated human umbilical vascular endothelial cells (p<0.05), while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). MicroRNA-140- 5p overexpression reduced the malondialdehyde content and apoptosis in oxidized low-density lipoproteinstimulated human umbilical vascular endothelial cells while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). Harpagide promoted microRNA-140-5p expression in human umbilical vascular endothelial cells after oxidized low-density lipoprotein stimulation (p<0.05). MicroRNA- 140-5p knockdown reversed the inhibitory effect of harpagide in human umbilical vascular endothelial cells (p<0.05). Harpagide up-regulates microRNA-140-5p to inhibit the oxidative stress and apoptosis of oxidized low-density lipoprotein-induced human umbilical vascular endothelial cells.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1156
R. B. Patel, R. V. Solanki, S. P. Chauhan, D. M. Patel
A simple, rapid and novel reverse phase-high performance liquid chromatography method was developed for quantification of molnupiravir in its capsule dosage form which is recently approved for phase III clinical trials in moderate coronavirus disease patients in India. The chromatographic separation of Molnupiravir was achieved on reverse phase-high performance liquid chromatography using Eclipse Plus C18 (150×4.6 mm, 5 µ) column with buffer (pH 4.5) and methanol (70:30 v/v) as mobile phase. Method was validated in accordance with recommendations of International Council for Harmonisation Q2 (R1) guidelines. The linearity of the method was found to be excellent over the concentration range of 49.80-149.40 µg/ml. The mean of the coefficient of determinations (r2, n=3) was found to be 0.9999. The precision values (percentage relative standard deviation) and overall percentage recovery was found to be acceptable. The proposed method effectively separated the drug from its degradation products. Hence, it can be used as a stability-indicating assay method for the routine analysis of molnupiravir in pharmaceutical formulations.
建立了一种简单、快速、新型的反相高效液相色谱法，用于定量莫努比拉韦胶囊剂型，该胶囊剂型最近被批准用于印度中度冠状病毒病患者的III期临床试验。采用Eclipse Plus C18 (150×4.6 mm, 5µ)色谱柱，以缓冲液(pH 4.5)和甲醇(70:30 v/v)为流动相，反相高效液相色谱法对Molnupiravir进行色谱分离。方法按照国际协调理事会Q2 (R1)指南的建议进行验证。在49.80 ~ 149.40µg/ml浓度范围内线性良好。决定系数(r2, n=3)的平均值为0.9999。精密度值(相对标准偏差百分比)和总体回收率是可以接受的。该方法有效地分离了药物及其降解产物。因此，它可以作为一种稳定性指示分析方法，用于药物制剂中莫那匹拉韦的常规分析。
{"title":"Development and Validation of Stability Indicating High Performance Liquid Chromatography Method for Determination of Molnupiravir in Capsule Dosage Form","authors":"R. B. Patel, R. V. Solanki, S. P. Chauhan, D. M. Patel","doi":"10.36468/pharmaceutical-sciences.1156","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1156","url":null,"abstract":"A simple, rapid and novel reverse phase-high performance liquid chromatography method was developed for quantification of molnupiravir in its capsule dosage form which is recently approved for phase III clinical trials in moderate coronavirus disease patients in India. The chromatographic separation of Molnupiravir was achieved on reverse phase-high performance liquid chromatography using Eclipse Plus C18 (150×4.6 mm, 5 µ) column with buffer (pH 4.5) and methanol (70:30 v/v) as mobile phase. Method was validated in accordance with recommendations of International Council for Harmonisation Q2 (R1) guidelines. The linearity of the method was found to be excellent over the concentration range of 49.80-149.40 µg/ml. The mean of the coefficient of determinations (r2, n=3) was found to be 0.9999. The precision values (percentage relative standard deviation) and overall percentage recovery was found to be acceptable. The proposed method effectively separated the drug from its degradation products. Hence, it can be used as a stability-indicating assay method for the routine analysis of molnupiravir in pharmaceutical formulations.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1089
Junjie Wang, Bo Han
Wang
王
{"title":"Kaempferol Promotes Apoptosis and Inhibited Autophagy in A549 Cells via MicroRNA-199/Mammalian Target of Rapamycin Axis","authors":"Junjie Wang, Bo Han","doi":"10.36468/pharmaceutical-sciences.1089","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1089","url":null,"abstract":"Wang","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1081
H. Mourya, N. Garud, R. Joshi, W. Akram, N. Singh
The purpose of this investigation is to formulate and evaluate the antihypertensive drug propranolol hydrochloride sustained-release bilayer tablets. In this formulation, one layer provides a loading dose through the immediate release of the drug and the other layer provides a maintenance dose for up to 12 h through controlled release. Different quantities of polymers such as Kyron T-314, Hydroxypropyl methylcellulose-K4M, and ethyl cellulose were used to make bi-layer tablets by direct compression. The compatibility study of pharmaceutical excipients was conducted through Fourier transform infrared spectroscopy studies and no interaction was found. The pre-compression parameter for the angle of repose, bulk density, tapped density and compressibility index was assessed on the produced granules and the findings were good. The tablets were evaluated for the post-compression parameters for thickness, hardness, friability and in vitro release studies. In vitro dissolution study was approved out for 12 h using United States Pharmacopeia dissolution apparatus I using phosphate buffer of pH 1.2 and 6.8 as dissolution medium. Hydroxypropyl methylcellulose-K4M and ethylcellulose were used in combination in all formulations but optimized formulation propranolol hydrochloride tablet 4 showed a higher rate of drug release up to 12 h as compared to the other formulation and optimized formulations propranolol hydrochloride tablet 4 follows the Higuchi model with non-fickian diffusion based on regression coefficient of the kinetics data of cumulative drug release from the dosage form.
{"title":"Formulation and Optimization of Propranolol Bilayer Tablets: A Potential Approach for Effective Management of Hypertension","authors":"H. Mourya, N. Garud, R. Joshi, W. Akram, N. Singh","doi":"10.36468/pharmaceutical-sciences.1081","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1081","url":null,"abstract":"The purpose of this investigation is to formulate and evaluate the antihypertensive drug propranolol hydrochloride sustained-release bilayer tablets. In this formulation, one layer provides a loading dose through the immediate release of the drug and the other layer provides a maintenance dose for up to 12 h through controlled release. Different quantities of polymers such as Kyron T-314, Hydroxypropyl methylcellulose-K4M, and ethyl cellulose were used to make bi-layer tablets by direct compression. The compatibility study of pharmaceutical excipients was conducted through Fourier transform infrared spectroscopy studies and no interaction was found. The pre-compression parameter for the angle of repose, bulk density, tapped density and compressibility index was assessed on the produced granules and the findings were good. The tablets were evaluated for the post-compression parameters for thickness, hardness, friability and in vitro release studies. In vitro dissolution study was approved out for 12 h using United States Pharmacopeia dissolution apparatus I using phosphate buffer of pH 1.2 and 6.8 as dissolution medium. Hydroxypropyl methylcellulose-K4M and ethylcellulose were used in combination in all formulations but optimized formulation propranolol hydrochloride tablet 4 showed a higher rate of drug release up to 12 h as compared to the other formulation and optimized formulations propranolol hydrochloride tablet 4 follows the Higuchi model with non-fickian diffusion based on regression coefficient of the kinetics data of cumulative drug release from the dosage form.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：